Skip to search formSkip to main contentSkip to account menu

rofecoxib

Known as: 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one, 4-[4'-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone, rofecoxib [Chemical/Ingredient] 
A synthetic, nonsteroidal derivative of phenyl-furanone with antiinflammatory, antipyretic and analgesic properties and potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (3)

Cyclooxygenase 2 InhibitorsLactonesSulfones
Degenerative polyarthritisDrug AllergyDysmenorrheaNCIt Antineoplastic Agent Terminology

Narrower (3)

MK 0966Vioxxrefecoxib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Effect of cyclooxygenase inhibitors on the micturition reflex in rats: correlation with inhibition of cyclooxygenase isozymes
To investigate the role of cyclooxygenase (COX) isozymes (COX‐1 and ‐2) in the regulation of bladder volume capacity (BVC) in… 
Highly Cited
2005
Highly Cited
2005
Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury.
Highly Cited
2004
Highly Cited
2004
Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain
Highly Cited
2004
Highly Cited
2004
Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL.
Highly Cited
2003
Highly Cited
2003
Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved.
2002
2002
Monolithic silica liquid chromatography columns for the determination of cyclooxygenase II inhibitors in human plasma.
Review
2001
Review
2001
Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors.
Review
2001
Review
2001
The ever-emerging anti-inflammatories. Have there been any real advances?
  • K. Rainsford
  • Journal of Physiology - Paris
  • 2001
  • Corpus ID: 21440382
Review
2001
Review
2001
The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase‐2, in humans
Highly selective inhibitors of cyclooxygenase‐2, such as rofecoxib, are hypothesized to have an improved gastrointestinal… 
Highly Cited
2000
Highly Cited
2000
Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
AbstractObjective: Prostaglandin synthesis is catalyzed by a constitutive cyclo-oxygenase isoform (COX-1) and an inducible… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)